地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771149750
传真:15172469628
邮箱:sales@amyjet.com

艾美捷科技代理Cell Culture Technologies品牌培养基产品品牌。
Cell Culture Technologies(CCT)是一家瑞士生物技术公司,成立于1992年,创始人为Ferruccio Messi博士;Cell Culture Technologies专注于细胞培养技术领域,拥有深厚的专业知识和技术积累,致力于开发和应用创新的细胞培养解决方案。经典产品:如Hektor G培养基(用于293细胞的日常维护与低温保存)、ChoMaster HTS培养基(用于CHO细胞的低温保存和稳定转染)、InVitrus培养基(用于肾源细胞的常规维护和低温保存)等。这些产品广泛应用于生物制药、细胞疗法、疫苗生产等领域。产品分类包括:
(1)最小培养环境中的细胞培养与冷冻保存:能够在极小的培养环境中对人类和动物细胞系进行培养和冷冻保存,保持细胞的活性和稳定性。
(2)化学定义的无蛋白和无肽培养基:开发了能够在这种培养基中生长的动物细胞生物工艺,为细胞培养提供了更为纯净和可控的环境。
(3)全合成细胞培养基的开发与大规模生产:成功开发出全合成细胞培养基,并实现了大规模生产,满足了生物制药、细胞疗法等领域对高质量细胞培养基的需求。
<<<<<< " data-original="http://novatein.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Cell Culture Technologies品牌培养基产品"> 艾美捷科技代理Cell Culture Technologies品牌培养基产品
<艾美捷科技代理Terracebiotech品牌全系列产品
Terracebiotech的专业技术源于加州大学旧金山分校医学中心的肺研究小组,该小组曾助力明确肺表面活性物质的特性,随后研发出其合成形式,用于治疗患有呼吸窘迫综合征的早产儿。凭借在肺细胞生物学领域超过 25 年的实践研究经验,Terracebiotech将其专业技术应用于推动医学研究的进一步创新,以改善人类健康。
Terracebiotech的抗体(在人体肺部中特异性靶向肺泡上皮1型或2型细胞)经验证,可高效、可靠地用于以下应用:免疫组织化学 (IHC);蛋白质印迹法 (Western Blotting);通过流式细胞分选技术 (FACS) 进行细胞分离;半定量斑点印迹 (Semi-Quantitative Dot Blots);磁性细胞分选 (Magnetic Cell Sorting);冷冻免疫电镜 (TEM Cryo-Immunohistochemistry)。

▍Terracebiotech产品列表
| 品名 | 货号 | Validated For | Production Host | Isotype | 规格 |
| Anti HT1-56 | TB-29AHT1-56 | IHC, Western Blots, FACS, magnetic Cell Sorting, Dot blots, and TEM | Mouse hybridoma cells | Mouse IgG1 | 1ml |
| Anti HT2-280 | TB-27AHT2-280 | IHC, Western Blots, FACS, magnetic Cell Sorting, Dot blots, and TEM | Mouse hybridoma cells | Mouse IgM | 1ml |
| Anti RT1-40 | TB-11ART1-40 | IHC, Western Blots, FACS, magnetic sell sorting, and dot blots. | Mouse hybridoma cells | Mouse IgG1 | 1ml |
| Anti RT2-70 | TB-44ART2-70 | IHC, FACS, magnetic Cell Sorting, and dot blots. | Mouse hybridoma cells | Mouse IgG3 | 1ml |

艾美捷科技代理VisualProtein品牌。
VisualProtein成立于2005年,致力于通过提供创新的科研产品与服务推动生物领域发展。凭借在蛋白质组学、免疫学及细胞学领域的专业深耕,不断拓宽科学研究的可能性边界。
Visual Protein的产品包括:
| 分类 | 品名 | 货号 |
| Proteomics | Western Blot Tool Box | BOX12 |
| Proteomics | Western Blot Tool Box with LuminolPen(LH03-10) | BOX12-03 |
| Proteomics | BlockPRO™ Blocking Buffer | BP01-1L |
| Proteomics | BlockPRO™ Protein-Free Blocking Buffer | BF01 |
| Proteomics | BlockPRO™ 1 Min Protein-Free Blocking Buffer | BM01 |
| Proteomics | LuminolPen™, HRP system | LH03 |
| Proteomics | LumiFlash™ Prime Chemiluminescent Substrate, HRP System | LF01-500 |
| Proteomics | LumiFlash™ Ultima Chemiluminescent Substrate, HRP System | LF08-500 |
| Proteomics | LumiFlash™ Infinity Chemiluminescent Substrate, HRP System | LF16-500 |
| Proteomics | LumiFlash™ Femto Chemiluminescent substrate, HRP System | LF24-100 |
| Proteomics | ExtractPRO™ Protein Extraction Reagent | EP05-30 |
| Proteomics | RIPA Cell Lysis Buffer | RP05 |
| Proteomics | Dual-Range™ BCA Protein Assay Kit | BC03-500 |
| Proteomics | Dual-Range™ Bradford Reagent (1X) | BR01-500 |
| Proteomics | Dual-Range™ Bradford Reagent (5X) | BR05-500 |
| Proteomics | Dual-Range™ Bradford Protein Assay Kit (5X) | BR05-500-K |
| Proteomics | VisPRO™ Blue-One Protein Stain | VB01-500 |
| Proteomics | VisPRO™ 5 Minute Protein Stain Kit | VP01 |
| Proteomics | 6X Laemmli SDS Sample Buffer, non-reducing(without beta-mercaptoethanol) | SBN06-15 |
| Proteomics | 6X Laemmli SDS Sample Buffer, reducing(with beta-mercaptoethanol) | SBR06-15 |
| Immunoassay buffer | ImmunoEX immunoassayDevelopment Kit(TBST) | IEX001 |
| Immunoassay buffer | ImmunoEX ImmunoassayDevelopment Kit (TBS) | IEX002 |
| Immunoassay buffer | ImmunoEX TBST Buffer | IE01-500 |
| Immunoassay buffer | ImmunoEX TBS Buffer | IE02-500 |
| Immunoassay buffer | mmunoEX Protein-BasedImmunoassay Buffer(TBST | IE03-500 |
| Immunoassay buffer | ImmunoEX Protein-Based lmmunoassay Buffer (TBS) | IE04-500 |
| Immunoassay buffer | ImmunoEX Protein-Free Immunoassay Buffer(TBST | IE05-500 |
| Immunoassay buffer | ImmunoEX Protein-Free Immunoassay Buffer (TBS) | IE06-500 |
| Supplement | CytoMore Cell RescueSupplement | CTO1-1BT |
| Supplement | HybriMore™ Hybridoma Culture Supplement* | HB01-1L |
| Buffer | PBS Buffer, 10X | PBS10-1L |
| Buffer | PBS Tween-20 Buffer, 10X | PBST10-1L |
| Buffer | TBS Buffer, 10X | TBS10-1L |
| Buffer | TBS Tween-20 Buffer, 10X | TBST10-1L |
| Buffer | TBS Tween-20 Buffer, 25X | TBST200P |
| Buffer | SDS-PAGE Running Buffer, 10X | RB10-1L |
| Buffer | SDS-PAGE Running Buffer, powder pack | RB500P |
| Buffer | Western Blot Transfer Buffer, 10X | WTB10-1L |
| Buffer | Western Blot Transfer Buffer, powder pack | WTB500P |
" data-original="http://novatein.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理VisualProtein品牌"> 艾美捷科技代理VisualProtein品牌
<艾美捷科技代理AxisPharm品牌全系列产品
AxisPharm是一家专业的分析服务提供商,致力于为科学研究界和工业界提供高质量的分析服务。凭借先进的仪器设备和专业的技术团队,AxisPharm在生物分析、化学分析和质量控制领域树立了良好的声誉。AxisPharm公司的产品线包括:PEG 连接子、用于药物递送的脂质、荧光染料、单击化学试剂、聚聚乙二醇,共聚物、可裂解的连接子、抗体和抗体药物偶联物ADC、ADC 有效载荷、细胞生物学试剂、脱氧核糖核酸、修饰语、探针、合成肽、目标特定链接器、硫醇反应性接头、酸反应性连接子、胺反应性连接子、羰基反应性连接子、探针、修饰符。

▍AxisPharm产品线
● PEG连接子:聚合物聚乙二醇是多分散聚乙二醇 (PEG) 聚合物,是一种从石油中提取的聚醚化合物,具有从工业制造到医药的许多应用。
● 用于药物递送的脂质:在药物递送系统中起着至关重要的作用,特别是在脂质体、脂质纳米颗粒或脂质胶束等脂质制剂中。脂质提供结构稳定性,增强药物溶解度,实现控释,并促进靶向药物递送。
● 荧光染料:也称为荧光团或荧光探针,是吸收一种波长的光并以更高波长发射的化合物,从而产生可见荧光。它们是生物学研究中的重要工具,用于标记和检测蛋白质、核酸和细胞等生物分子,从而在显微镜、流式细胞术和实时荧光定量 PCR 等应用中实现灵敏和精确的可视化。
● 点击化学试剂:具有高特异性和最少的副产物,简化了复杂的合成过程。因此,它们在分子生物学、材料科学和药物化学中发挥着至关重要的作用。
● 聚合物聚乙二醇:多分散聚乙二醇 (PEG) 聚合物,是一种从石油中提取的聚醚化合物,具有从工业制造到医药的许多应用。
● 可裂解连接子:一类重要的分子,广泛应用于药物发现、化学生物学和材料科学等各个领域。这些连接子充当两个或多个分子实体之间的连接桥,可以在特定条件下选择性地裂解,从而释放附着的分子。这一特性使它们成为生物活性化合物靶向药物递送、成像和控释的有吸引力的工具。
● 抗体及抗体-药物偶联物及细胞生物学试剂:种类丰富可选择。
● ADC有效载荷:作为 ADC 的三个主要成分之一,有效载荷是高活性和有毒的药物分子,通过化学连接子附着在抗体上。有效载荷可以是小分子、蛋白质毒素、生物活性肽、酶,甚至放射性核素。通过适当的接头与适当的载体系统耦合的有效载荷可能会显示出靶向药物递送的特异性和有效性的提高。
● 脱氧核糖核酸:DNA 是脱氧核糖核酸的缩写,是一种包含所有生物体发育和功能的遗传指令的分子。DNA 由四个基本组成部分组成,称为核苷酸,由糖、磷酸基团和含氮碱基组成。
● 改性剂:改变其他分子或材料特性的化合物。在药物研发领域,改性剂在新型药物递送系统和生物医学设备的设计和优化中发挥着至关重要的作用。一种常见的改性剂类型是官能团,它是赋予分子特定化学和物理性质的原子的特定排列。
● 探针:AxisPharm 提供各种靶标特异性探针,例如叶酸 PEG、生物素 PEG、PROTAC PEG、荧光染料探针和图像探针。探针是一类含有官能团的化合物,旨在选择性地与生物分子(如酶、受体和核酸)相互作用。这些官能团包括荧光染料、生物素和亲和标签等,可以检测和定量复杂生物系统中的特定分子。
| Different Types of Polyethylene Glycol PEG Linkers in Stock | ||||
| Acid PEG | Diketone PEG | Non-PEG linker | PFP ester PEG | Sugar PEG β-Glucuronide Linker |
| Aldehyde PEG | DNP PEG | PEG-t-butyl ester | Phosphonate PEG | Sulfonic acid PEG |
| Alkyne PEG | DBCO PEG | PEG-X-PEG | Polymer PEG | TCO PEG |
| Amino PEG | DSPE PEG | Peptide Linkers | Propargyl PEG | Tetrazine PEG |
| Aminooxy PEG | Fluorescent PEG | Lipid PEG | PROTAC Linker | Homobifunctional PEG |
| Azide PEG | Fmoc PEG | M-PEG | Silane PEG | Bromo PEG |
| BCN-PEG | Folate PEG | Maleimide PEG | SPDP PEG | Tosylate PEG |
| Benzyl-PEG | Thiol PEG | MeNH-PEG | Branched PEG | Bis-Sulfone PEG |
| Biotin PEG | Hydrazide PEG | NHS ester PEG | HyNic PEG | DOTA Reagent DOTA PEG |
| Bis-PEG-acid | Hydroxy PEG | Boc-PEG | Bis-PEG-NHS | Iodo PEG |
| Bis-PEG-NHS | Cleavable Linkers | |||
| Lipids for Drug Delivery | ||||
| Biotinyl Cap PE | Dodecanyl PE | Other Lipid | Phosphatidylcholine | Phosphatidylethanolamine |
| Biotinyl PE | Glutaryl PE | PDP PE | Phosphoglycerol | Ptd Thioethanol |
| Caproylamine PE | Ionizable Lipid | PE MCC | Phosphoserine | Succinyl PE |
| Cationic Lipid | Lipid PEG | Cyanur PE | MPB PE | |
| Fluorescent Dye | ||||
| AF Dyes | Cyanine Dyes | MB Dyes | Rhodamine Dye | Rox (carboxy-X-rhodamine) Dye |
| APDye Fluors | DNP PEG | JOE | R6G | Peptide Labeling Reagents |
| Bodipy Probes | Fluorescein (FAM) | Pyrene Probes | TAMRA Dye | Classic Fluorescent Dyes |
| IR Fluors | Quenchers | Coumarin 343 | ||
| Click Chemistry Tools & Reagents | ||||
| Alkyne PEG | BCN-PEG | PTAD Linker | Tetrazine PEG | Click Chemistry Auxiliary Reagents |
| Azide PEG | DBCO PEG | TCO PEG | Methylcyclopropene Linkers | |
| Polymer PEG | ||||
| Acrylate | Biotin | Fmoc | Lipoamide | Silane |
| Active ester | Boc | Folate | Maleimide | Stearic acid |
| Aldehyde | Carboxylic acid | guanlian1010 | MW 2000 | TCO |
| Amine | Cholesterol | Hydrazide | MW 5000 | Thiol |
| Azide | DBCO | Hydroxyl | Polysarcosine | |
| Cleavable Linkers | ||||
| -S-S-Cleavable | PC Cleavable | Disulfide Linkers | Dde Cleavable Linkers | β-Glucuronide Linkers |
| Cleavable Peptide | diazo biotin probes | DTSSP crosslinker | Photocleavable Biotin | |
| Antibody and Antibody Drug Conjugate (ADC) | ||||
| Inotuzumab | Trastuzumab | Enfortumab | Labetuzumab govitecan | Mirvetuximab soravtansine (solution) |
| Vobramitamab | Disitamab | Mirzotamab | Loncastuximab tesirine | Trastuzumab deruxtecan (solution) |
| Polatuzumab | Ozuriftamab | Brentuximab | Trastuzumab deruxtecan | ADC Control Human IgG1-Deruxtecan (DAR 8) |
| Gemtuzumab | Inebilizumab | Datopotamab | Cofetuzumab pelidotin | Glembatumumab vedotin |
| Daratumumab (PBS) | Denintuzumab | Sacituzumab govitecan | Belantamab mafodotin | Trastuzumab duocarmazine |
| Praluzatamab | Naratuximab | Tisotumab | Enfortumab vedotin-ejfv | Trastuzumab emtansine (solution) |
| Lorvotuzumab | Rolinsatamab | Trastuzumab emtansine | Telisotuzumab vedotin | Enfortumab vedotin-ejfv (solution) |
| Izeltabart | Mipasetamab | Datopotamab deruxtecan | Gemtuzumab ozogamicin | Brentuximab vedotin (solution) |
| Lupartumab | Iladatuzumab | ORM-5029 | Cantuzumab ravtansine | Depatuxizumab mafodotin |
| Cantuzumab | Briobacept | Ifinatamab deruxtecan | Tusamitamab ravtansine | ADC Control Human IgG1-Deruxtecan (DAR 4) |
| Lonigutamab | Tamrintamab | Tisotumab vedotin | Zilovertamab vedotin | Depatuxizumab MMAE |
| Moxetumomab | Sacituzumab | Disitamab vedotin | Polatuzumab vedotin | ADC Control Human IgG1-vcMMAF |
| Azintuxizumab | Upifitamab | Belantamab | Pivekimab | Sacituzumab govitecan (solution) |
| Lifastuzumab | Glembatumumab | Patritumab deruxtecan | Farletuzumab ecteribulin | |
| Payloads and Linker modified Payloads | ||||
| Exatecan | Belotecan HCl | SGD-1882 | Dolastatin 10 | MC-Val-Cit-PAB-Doxorubicin |
| SN 38 | Gimatecan | MMAF | Calicheamicin | Gly3-Val-Cit-PAB-MMAE |
| Amrubicin | Taltobulin | Auristatin E | Eribulin Mesylate | SuO-Glu-Val-Cit-PAB-MMAE |
| Mitomycin C | Dxd | Chlorambucil | Soblidotin (Auristatin PE) | Fmoc-G-amino-CH2O acetyl-Exetecan |
| Deruxtecan analog | Lurtotecan | PF-06380101 | Deruxtecan analog 2 | DM1-MCC-PEG3-Biotin |
| sulfo-SPDB-DM4 | Exatecan mesylate | Auristatin F | Paclitaxel | GGFG-amino-CH2O-acetyl Exetecan |
| Rubitecan | MC-DM1 | MMAF-methyl ester | MC-MMD10 | Mal-PEG8-Val-Cit-PAB-MMAE |
| (4-NH2)-Exatecan | Irinotecan | Doxorubicin-SMCC | SPDB-DM4 | DBCO-PEG4-Val-Cit-PAB MMAF |
| Topotecan | PNU-159682 | MMAD | 10-Hydroxycamptothecin | Topotecan Hydrochloride |
| CL2A-SN38 | DM4 | 7-Ethylcamptothecin | ||
| Cell Biology Reagents | ||||
| Neuro-DiO, lipophilic tracer | VU (5-Vinyl-uridine) | CM-DiI, lipophilic tracer | LumiTracker ER Green | ER-Tracker Red (BODIPY TR Glibenclamide) |
| Annexin V-AF 647 conjugate | DAPI, blue fluorescent nucleic acid stain | Propidium Iodide | Deep-Red Fluorescent Nissl Stain | MitoCLox, mitochondrial lipid peroxidation probe |
| Annexin V-AF 488 conjugate | LumiTracker Mito Rhodamine 123 | LumiTracker Mito Green FM | RAPID DiI, lipophilic tracer | Laurdan (6-Dodecanoyl-2-dimethylaminonaphthalene) |
| Annexin V, His Tag | Thiazole Orange | SynaptoProbe® Red | LumiTracker ER Red | Linear Polyacrylamide for Nucleic Acid Precipitation |
| DiD, lipophilic tracer | RH 237, potentiometric probe | SynaptoProbe® Green | RAPID DiO, lipophilic tracer | Fluo-4 AM, green fluorescent calcium indicator |
| DiR, lipophilic tracer | Hoechst 33342, blue fluorescent nucleic acid stain | LumiTracker® Mito Red FM | DiI, lipophilic tracer | YODi-1, green fluorescent nucleic acid stain |
| DNA | ||||
| CPG solid supports | DNA Stains | Modified Triphosphates | phosphoramidite | |
| Probes | ||||
| Biotin PEG | Folate PEG | Image Probes | PROTAC Linker | |
| Amine reactive Linkers | ||||
| Acid PEG | Aldehyde PEG | Bromo PEG | Maleimide PEG | NHS ester PEG |
▍AxisPharm提供的服务
● 蛋白质组学服务:提供质谱分析、蛋白质鉴定和定量服务。专注于生物标志物分析,帮助客户在复杂的生物样本中发现和验证潜在的生物标志物。
● 代谢组学服务:利用先进的LC-MS/MS技术进行代谢物分析,提供通路洞察,帮助客户理解代谢途径和生物过程。
● 高级LC-MS/MS服务:用于PK分析和HPLC分离,确保高精度和高效率的研究结果,提供PK/PD研究,支持药物开发和临床前研究。
▍AxisPharm部分产品列表
| Cat# | Name | M.W. | Purity |
| AP15197 | Exatecan | 435.45 | ≥98% |
| AP15072 | SN 38 | 392.4 | ≥95% |
| AP15226 | Amrubicin | 483.47 | ≥98% |
| AP15664 | Mitomycin C | 334.3 | ≥98% |
| AP15203 | 10-Hydroxycamptothecin | 364.35 | ≥95% |
| AP15204 | 7-Ethylcamptothecin | 376.41 | ≥95% |
| AP15210 | Rubitecan | 393.35 | ≥95% |
| AP15211 | (4-NH2)-Exatecan | 403.43 | ≥95% |
| AP15206 | Topotecan | 421.5 | ≥95% |
| AP15207 | Topotecan Hydrochloride | 425.5 | ≥95% |
| AP15202 | Belotecan HCl | 433.5 | ≥95% |
| AP15208 | Gimatecan | 447.5 | ≥95% |
| AP15227 | Taltobulin | 473.65 | ≥99% |
| AP15201 | Dxd | 493.48 | ≥95% |
| AP15209 | Lurtotecan | 518.56 | ≥95% |
| AP15196 | Exatecan mesylate | 531.55 | ≥98% |
| AP15200 | Deruxtecan analog 2 | 579.58 | ≥95% |
| AP15205 | Irinotecan | 586.68 | ≥95% |
| AP15224 | PNU-159682 | 641.62 | ≥98.24% |
| AP15220 | Soblidotin (Auristatin PE) | 701.98 | ≥95% |
| AP15225 | SGD-1882 | 725.8 | ≥98% |
| AP15213 | MMAF | 732 | ≥95% |
| AP15216 | Auristatin E | 732 | ≥95% |
| AP15311 | Chlorambucil | 304.21 | ≥98 |
| AP15219 | PF-06380101 | 743.01 | ≥95% |
| AP15214 | Auristatin F | 746 | ≥95% |
| AP15215 | MMAF-methyl ester | 745.99 | ≥98% |
| AP15187 | Doxorubicin-SMCC | 762.8 | ≥98% |
| AP15217 | MMAD | 771.06 | ≥98% |

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://novatein.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
<艾美捷科技代理VIDIA品牌全系列产品
VIDIA Ltd.是一家捷克私营生物技术公司,创立于1991年,是体外诊断试剂(IVD)生产商,产品应用于人类医学诊断和环境监测领域。自2003年起,公司已通过ISO 9001和ISO 13485认证。所有IVD产品均获得CE认证。其产品设计具有高稳定性和长保质期,且易于使用。

▍VIDIA公司产品线
● ELISA-VIDITEST™ 免疫酶联检测试剂盒:基于酶联免疫吸附法,具有抗体定量/半定量/定性分析、鞘内抗体合成测定以及抗体亲和力评估的检测功能。
● MONO-VIDITEST™ 单次检测盒:基于间接ELISA方法,用于测定样品中特异性抗体的含量。这些试剂盒旨在对血清、血浆、脑脊液和滑膜液样本中的 IgA、IgM 和 IgG 类抗体进行定量/半定量评估。
● LIA-VIDITEST:基于硝酸纤维素膜条的酶联线性免疫印迹法,单次运行即可并行检测多个样本的 IgM 和 IgG 抗体,经验证适用于全自动或半自动的 RoboBlot、BeeBlot、B20 分析仪。
● RAPID-VIDITEST 快速检测试剂盒:诊断型快速色谱免疫分析法,操作简便,结果易判读,可定性检测多种病毒、细菌、寄生虫的抗原。
● IF-VIDITEST:应用于多种感染的血清学诊断,具有高灵敏度与高特异性,操作流程简便的特点。
▍VIDIA部分产品列表
| 品名 | 规格 | 货号 |
| ELISA-VIDITEST anti-complement factor H | 48 wells quantitative | ODZ-166 |
| ELISA-VIDITEST EDUCO Diagnostic | 96 wells 6 doublestrips | ODZ-191 |
| CMV - CI combi r.t.u. | 1 ml | ODZ-264 |
| VZV - CI combi r.t.u. | 1 ml | ODZ-289 |
| HSV-1 - CI nativ r.t.u. | 1 ml | ODZ-314 |
| HSV-2 - CI nativ r.t.u. | 1 ml | ODZ-315 |
| CMV - CI nativ conc. | 0,5 mg | ODZ-319/05 |
| VZV - CI nativ conc. | 0,1 mg | ODZ-320 |
| HSV-1 - CI nativ conc. | 0,1 mg | ODZ-321 |
| HSV-2 - CI nativ conc. | 0,1 mg | ODZ-322 |
| Control - CI r.t.u. (pro CMV, VZV) | 1 ml | ODZ-365 |
| Control - CI r.t.u. (pro HSV-1, HSV-2) | 1 ml | ODZ-366 |
| ELISA-VIDITEST Bisphenol A | 96 wells quantitative | ODZ-041 |
| ELISA-VIDITEST Microcystin-LR | 96 wells quantitative | ODZ-165 |
| ELISA-VIDITEST pNF-H (Neurofilament-H) | 96 wells quantitative | ODZ-437 |
| ELISA-VIDITEST anti-HSV1+2 IgG | 96 wells semiquantitative | ODZ-169 |
| ELISA-VIDITEST anti-HSV1+2 IgM | 96 wells semiquantitative | ODZ-234 |
| ELISA-VIDITEST anti-HSV1+2 IgA | 96 wells semiquantitative | ODZ-283 |
| MONO-VIDITEST anti-HSV IgG | 12 tests | KZ-140-12 |
| MONO-VIDITEST anti-HSV IgM | 12 tests | KZ-141-12 |
| ELISA-VIDITEST anti-EBNA-1 EBV IgG, doublestrip | 96 wells semiquantitative | ODZ-015 |
| ELISA-VIDITEST anti-EBNA-1 EBV IgG | 96 wells semiquantitative | ODZ-001 |
| ELISA-VIDITEST anti-EBNA-1 EBV IgM | 96 wells semiquantitative | ODZ-002 |
| ELISA-VIDITEST anti-VCA EBV IgG | 96 wells semiquantitative | ODZ-265 |
| ELISA-VIDITEST anti-VCA EBV IgG (CSF) | 96 wells quantitative | ODZ-084 |
| ELISA-VIDITEST anti-VCA EBV IgG and IgG avidity | 96 wells semiquantitative | ODZ-175 |
| ELISA-VIDITEST anti-VCA EBV IgM | 96 wells semiquantitative | ODZ-005 |
| ELISA-VIDITEST anti-VCA EBV IgA | 96 wells semiquantitative | ODZ-096 |
| ELISA-VIDITEST anti-EA (D) EBV IgG | 96 wells semiquantitative | ODZ-006 |
| ELISA-VIDITEST anti-EA (D) EBV IgM | 96 wells semiquantitative | ODZ-007 |
| ELISA-VIDITEST anti-EA (D) EBV IgA | 96 wells semiquantitative | ODZ-254 |
| MONO-VIDITEST anti-VCA EBV IgG | 12 tests | KZ-100-12 |
| MONO-VIDITEST anti-VCA EBV IgM | 12 tests | KZ-101-12 |
| MONO-VIDITEST anti-VCA EBV IgA | 12 tests | KZ-102-12 |
| MONO-VIDITEST anti-VCA EBV IgG avidita | 12 tests | KZ-103-12 |
| MONO-VIDITEST anti-EBNA-1 EBV IgG | 12 tests | KZ-110-12 |
| MONO-VIDITEST anti-EBNA-1 EBV IgM | 12 tests | KZ-111-12 |
| ELISA-VIDITEST anti-CMV IgG (CSF) | 96 wells quantitative | ODZ-102 |
| ELISA-VIDITEST anti-CMV IgG and IgG avidity | 96 wells semiquantitative | ODZ-177 |
| ELISA-VIDITEST anti-CMV IgM | 96 wells semiquantitative | ODZ-402 |
| ELISA-VIDITEST anti-CMV IgA | 96 wells semiquantitative | ODZ-164 |
| ELISA-VIDITEST anti-VZV IgG | 96 wells semiquantitative | ODZ-168 |
| ELISA-VIDITEST anti-VZV IgG (CSF) | 96 wells quantitative | ODZ-087 |
| ELISA-VIDITEST anti-VZV IgG and IgG avidity | 96 wells semiquantitative | ODZ-233 |
| ELISA-VIDITEST anti-VZV IgM | 96 wells semiquantitative | ODZ-197 |
| ELISA-VIDITEST anti-VZV IgA | 96 wells semiquantitative | ODZ-284 |
| MONO-VIDITEST anti-EA(D) EBV IgG | 12 tests | KZ-120-12 |
| MONO-VIDITEST anti-EA(D) EBV IgM | 12 tests | KZ-121-12 |

艾美捷科技代理DiscoverX 品牌。
DiscoverX 是一家专注于药物发现和生物分析的公司,提供创新的高通量筛选技术和生物分析工具,支持药物研发、毒理学研究和生物标志物发现。Eurofins DiscoverX® 是值得信赖的药物发现和开发产品解决方案供应商。作为 Eurofins Discovery 的产品部门,以及 Eurofins BioPharma 全球网络的一部分,DiscoverX 在过去二十年里通过为拯救生命的治疗药物的发现和开发做出贡献,这些药物使用了值得信赖和经过验证的细胞基检测产品,用于筛选和验证数十亿个数据点。DiscoverX 产品组合包括适合目的的解决方案,从即用型均质检测试剂盒、稳定的工程细胞系、膜准备、重组蛋白质/酶和合格试剂。
DiscoverX 主要产品和服务包括:
(1)高通量筛选平台:提供基于细胞和酶的高通量筛选平台,用于药物发现和毒性测试。
(2)生物分析工具:提供多种生物分析工具,如报告基因检测、细胞活性检测和蛋白质相互作用分析。
(3)定制服务:根据客户需求,提供定制化的高通量筛选和生物分析服务。
(4)技术咨询与支持:提供药物发现和生物分析相关的咨询和技术支持服务。
<艾美捷科技代理Lifeome品牌全系列产品
Lifeome公司致力于基因组学、转录组学及蛋白质组学领域的产品研发、生产与市场化,提供全方位的研究产品与服务体系。Lifeome核心产品包括生长因子、抗体、病毒蛋白、重组蛋白,基因工程克隆载体等。
▍Lifeome公司的服务
● 定制抗体开发服务:多克隆与单克隆抗体解决方案,应用于蛋白定量检测、细胞/组织定位分析(活体或固定样本),由政府认证实验室提供全流程生产服务;
● 高端多肽合成解决方案:由平均从业5年以上的技术专家操作顶级合成系统,覆盖从基础科研到工业级生产需求;
● 蛋白质表达与纯化:其培养简便、产量高,能快速获得免疫原。

| Cytokines | ||||
| Bone Morphogenetic Protein | Beta Defensin | Endoglin | Interleukin | Serum Amyloid A |
| Leukemia Inhibitory Factor | Betacellulin | Flt3 Ligand | Apoliproteins | Thrombopoietin |
| B Cell Activating Factor | Angiopoietin | Hedgehog Progein | Others | Trefoil Factor |
| B type Natriuretic Peptide | EBI3 | Interferon | Resistin | Visfatin |
| Tumor Necrosis Factor | ||||
| Chemokines | ||||
| ENA 78 | IL-8 (CXCL8) | MDC (CCL22) | NAP-2 (CXCL7) | SDF (CXCL12) |
| Lymphotactin (XCL1) | IP-10 (CXCL10) | MEC (CCL28) | Others | TARC (CCL17) |
| Platelet Factor-4 (CXCL4) | Eotaxin | MIG (CXCL9) | GRO | Rantes (CCL5) |
| I-TAC (CXCL11) | MCP | MIP | ||
| Recombinant Proteins | ||||
| ADP-Ribosylation Factor | Cardiac Troponin | Superoxide Dismutase | Profilin | Streptavidin |
| Synaptosomal Associated Protein | Chromogranin | Hypoxia-Inducible Factor | BID | HSP |
| TNF receptor-Associated Factor | cJun | U6 Small Nuclear RNA | Protein-A, A/G & G | Synaptobrevin |
| Microtubule-Associated Protein | Annexin | Melanoma Antigen | RAS Oncogene | Albumin |
| Myelin Oligodendrocyte GlycoP | Aprotinin | Coaggulation Factors | Calbindin | Syndecan |
| Translation Initiation Factors | Collagen | Coagulation Factors | Cell Division Cycle | Synuclein |
| B Cell Lymphoma | Crystallin | Myoglobin | Centromere Protein | Thioredoxin |
| Beta 2 Microglobulin | Cystatin | Myosin Light Chain | Ribosomal Protein | Thrombin |
| Programmed Cell Death | Cytokeratin | DNA-Damage Protein | Secretagogin | Allergy |
| C-Reactive Protein | Nanog | Natural Proteins | Selectin | Transferrin |
| Ras-Related C3 Botulinum Tox... | Dynein Light Chain | Non-Metastatic Cells | Septin | Transgelin |
| Calcium Binding Protein | Ephrin | Visinin-Like Protein | Serpin | Avidin |
| Small Nuclear Ribonucleo... | ER Proteins | Outer Membrane Protein | CD Antigens | Tropomyosin |
| Chloride Intracellular Channel | FABP | p53 | Sirtuin | Trypsin |
| Sex Determining Region Y Box | Ferritin | PCNA | SMAD | Killer Cell |
| Regenerating Islet-Derived | Fibronectin | POU Class | Calmodulin | Ubiquitin |
| Regulator of G-Protein Signaling | Prefoldin | High-Mobility Group | Stathmin | Vimentin |
| Antibodies | ||||
| Anti Human Chemokine | Anti Viral | Anti Human Cytokine | Anti Human Enzymes | Anti Human HSP |
| Anti Human Lymphocyte | ELISA Pairs | Anti Mouse Lymphocyte | Anti Expression Tags | Anti Mouse Cytokine |
| Polyclonal Rabbit Antibodies | Rare Antibodies | |||
| Viral Proteins | ||||
| Borrelia | EBV | Hepatitis C | Malaria | Rubella |
| Chagas | Encephalitis | Hepatitis D | Measles | S. Typhi |
| Chikungunya | West Nile | Hepatitis E | Mumps | SARS |
| Chlamydia | Hantavirus | Herpes | Mycoplasma | Shiga Like Toxin |
| Cytomegalo | HBsAg | HIV | Norovirus | Toxoplasma |
| Dengue | Hepatitis A | HTLV | Papillomavirus | Treponema |
| Ebola | Hepatitis B | Influenza | Parvovirus | Varicella |
| Feline Leukemia Virus | Zika | |||
| Growth Factors | ||||
| Melanoma Inhibitory Proteins | Galectin | Keratinocyte GF | Omentin | Prolactin |
| Colony Stimulating Factor | Growth Hormone | Leptin | Oncostatin-M | RANK Ligand |
| Hepatocyte Growth Factor | CTGF | Macrophage Migration IF | Osteoprotegerin | Retinol Binding P |
| Epidermal Growth Factor | IGFBP | Activin | Others | Stem Cell Factor |
| Transforming Growth Factor | Insulin | Myostatin | PDGF | Erythropoietin |
| Fibroblast Growth Factor | Insulin-like GF | Noggin | Placental Lactogen | VEGF |
| Research Reagents | ||||
| Biochemical Kits | CoVID19 | CRISPR-Cas9 | Media/Plates | Molecular Markers |
| Nucleic Acids Purification | Seamless Cloning | |||
| Primary Cells | ||||
| Dog | Goat | Mouse | Rabbit | Rat |
| ELISA | ||||
| Chemiluminescent | HRP | Specialty Kits | ||
| Xpress Clones | - | cis Element Reporter | ||
| Bacterial Clones | Mammalian Clones | - | Hygromycin Kits | Neomycin Kits |
▍Lifeome部分产品列表
<| 品名 | 货号 | 规格 |
| Primary AC Cell, Dog | CSI003Ca01-500k | 5x10^5 |
| Primary AEC Cell, Dog | CSI006Ca01-500k | 5x10^5 |
| Primary AFC Cell, Dog | CSI008Ca01-500k | 5x10^5 |
| Primary ASMC Cell, Dog | CSI153Ca01-500k | 5x10^5 |
| Primary BMMC Cell, Dog | CSI164Ca01-500k | 5x10^5 |
| Primary BMMSCs Cell, Dog | CSI083Ca01-500k | 5x10^5 |
| Primary MC Cell, Dog | CSI007Ca01-500k | 5x10^5 |
| Primary NDF Cell, Dog | CSI088Ca01-500k | 5x10^5 |
| Primary NPC Cell, Dog | CSI113Ca01-500k | 5x10^5 |
| Primary OB Cell, Dog | CSI102Ca01-500k | 5x10^5 |
| Primary OF Cell, Dog | CSI138Ca01-500k | 5x10^5 |
| Primary RCEC Cell, Dog | CSI067Ca01-500k | 5x10^5 |
| Primary SEC Cell, Dog | CSI112Ca01-500k | 5x10^5 |
| Primary TDSC Cell, Dog | CSI255Ca01-500k | 5x10^5 |
| Primary TSMC Cell, Dog | CSI068Ca01-500k | 5x10^5 |
| Primary AC Cell, Goat | CSI003Cp01-500k | 5x10^5 |
| Primary ASMC Cell, Goat | CSI153Cp01-500k | 5x10^5 |
| Anti-APOB100 Antibody | A90603Hu01-1 | 100 ug |
| Anti-APOC2 Antibody | PAB77963-1 | 100 ug |
| Anti-HPR Antibody | A92000Hu01-1 | 100 ug |
| Antibody to Mouse Insulin (INS) | A90448Mu01-100ug | 100 ug |
| Antibody to Mouse Insulin (INS) | A90448Mu01-50ug | 50 ug |

艾美捷科技代理Dovetail Genomics品牌全系列产品
Dovetail Genomics公司成立于2013年,是染色体级别基因组组装领域的创新者,Dovetail Genomics公司正在解决包括染色质拓扑结构分析、大小体细胞变异检测、从头染色体组装和单倍型定相在内的复杂问题。Dovetail Genomics通过其专利的Hi-C/Omini-C技术,填补了短读长测序无法完成高质量组装的空白,产品广泛应用于表观遗传学、发育生物学、癌症研究、进化生物学、传染病等领域。

▍Dovetail Genomics公司的产品
| Dovetail Assay | ||||||
| Application | LinkPrep™ | Micro-C | HiChIP | Pan Promoter | Omni-C | |
| Genetic Variation | Large Structural Variant Detection Genotyping | √ | ||||
| Genotyping | √ | |||||
| Haplotype Phasing | √ | √ | ||||
| Chromatin Topology | Targeted Enhancer- Promoter Interactions | |||||
| Nucleosome-level Chromatin Topology | √ | |||||
| Whole Genome Rapid High-Resolution Topology | √ | |||||
| Protein Anchored Topology | √ | |||||
| Genetic Genome Assembly | Genome Scaffolding | √ | √ | |||
| Hybrid Capture Compatible | √ | √ | √ | |||
▍Dovetail® LinkPrep™ Kit
采用Tn5转座酶实现染色质均匀片段化,确保捕获无偏差的完整染色质三维构象。产品特点:
● 单日工作流:样本→测序文库仅需8小时(传统Hi-C需3-5天)
● 零专用设备:兼容常规分子生物学实验室
● 实现单倍型定相组装(Haplotype-resolved)
● 同步捕获全谱变异:SNV/InDel/CNV/SV(灵敏度达95%)
● 适用于基因组拓扑结构、遗传变异、基因组组装
▍Dovetail® Micro-C Kit
获取核小体分辨率的三维基因组图谱,针对需要单核小体级别精细拓扑图谱的研究(解析150-200 bp染色质构象),本技术可逐层解锁基因组三维结构。其在1千碱基对(kbp)以下分辨率呈现的高信噪比特性,使研究者能够以显著降低的成本构建高质量的染色质互作矩阵。产品特点:
● 核小体级精度:直接解析 150-200 bp染色质基本单元(单核小体)的空间构象,突破传统Hi-C技术分辨率限制(通常>1 kbp)
● 超高信噪比优势:在亚千碱基级别消除背景噪音,精确捕获微尺度拓扑关联域(如增强子-启动子互作)
● 成本降低:相较冷冻电镜或ChIA-PET等方法,实验成本下降60-80%; 矩阵数据质量提升(矩阵信噪比 > 95%,传统方法约70-85%)
▍Dovetail® Pan Promoter Kit
专为绘制“基因启动子-调控元件”三维互作图谱设计,通过靶向富集技术实现高分辨率、低成本的染色质构象分析。
▍Dovetail® HiChIP Kit
抗体导向的精准三维基因组捕获系统,融合Hi-C空间架构捕获与ChIP靶向富集技术,实现对特定蛋白(如CTCF、Cohesin、组蛋白修饰)介导的染色质互作进行纳米级分辨率解析。产品特点:
● 分辨率:200 bp(单核小体水平)
● 灵敏度:检测低频互作(≥5个细胞中1次事件)
● 特异性:抗体结合位点富集度 >100X;非特异性背景 <2%
● 样本兼容性:冰冻组织、FFPE样本、单细胞悬液
▍Dovetail® Omni-C® Kit
通过Tn5转座酶同时捕获染色质空间互作与酶切位点信息,核心优势:
● 高分辨率:精准解析拓扑关联结构域(TADs)、染色质环
● 多组学整合:单次实验同步检测染色质构象+基因变异(SNV/InDel/CNV/SV)
● 样本兼容性:支持微量样本(>50mg组织/ >10,000个细胞)
" data-original="http://novatein.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Dovetail Genomics品牌全系列产品"> 艾美捷科技代理Dovetail Genomics品牌全系列产品
<艾美捷科技代理Research Products International(RPI)品牌全系列产品
Research Products International成立于1970年,总部位于伊利诺伊州展望山市 (Mount Prospect, Illinois),是化学品与生物化学品领域的领先制造商和供应商,并且获得ISO 9001:2008和GMP ISO 22716:2007认证。公司的五大主要产品线涵盖逾7,000种适用于植物与生命科学研究实验室的产品。除了自主生产的产品外,RPI还代理大多数领先品牌的科学设备。RPI公司的产品线包括抗生素、生物化学品、缓冲液、培养基以及实验室耗材。

▍Research Products International(RPI)部分产品列表
| 品名 | 货号 | CAS号 | 分子量 | 分子式 | Solubility | 储存温度 |
| 17-AAG | A20045 | 75747-14-7 | 585.7 | C31H43N3O8 | DMSO, Methanol | -20°C |
| Actinomycin D | A10025 | 50-76-0 | 1255.5 | C62H86N12O16 | DMSO, ethanol | 2-8°C |
| Allopurinol | A21000 | 315-30-0 | 136.11 | C5H4N4O | 1M NaOH | Room Temperature |
| Amdinocillin | A91690 | 32887-01-7 | 325.43 | C15H23N3O3S | - | 2-8°C |
| Amikacin | A20530 | 37517-28-5 | 585.6 | C22H43N5O13 | Water | 2-8°C |
| Amikacin Disulfate | A20540 | 39831-55-5 | 781.77 | C22H43N5O13 • 2H2SO4 | Water | 2-8°C |
| Amoxicillin Trihydrate | A40020 | 61336-70-7 | 419.5 | C16H19N3O5S • 3H2O | Water | 2-8°C |
| Amphotericin B | A40030 | 1397-89-3 | 924.1 | C47H73NO17 | DMSO | -20°C |
| Amphotericin B 250ug/ml Solution | A40035 | 1397-89-3 | 924.1 | C47H73NO17 | Water | -20°C |
| Ampicillin Trihydrate | A40050 | 7177-48-2 | 403.46 | C16H19N3O4S • 3H2O | 1M HCl | 2-8°C |
| Ampicillin, Sodium Salt | A40040 | 69-52-3 | 371.4 | C16H18N3O4SNa | Water | 2-8°C |
| Anisomycin from streptomyces griseolus | A50100 | 22862-76-6 | 265.3 | C14H19NO4 | Ethanol | 2-8°C |
| Apramycin Sulfate | A50020 | 65710-07-8 | 637.6 | C21H41N5O11 - H2SO4 | Water | 2-8°C |
| Bacitracin | B32000 | 1405-87-4 | 1422.69 | C66H103N17O16S | Water, Ethanol, and Methanol | 2-8°C |
| Bafilomycin B1 | B52100 | 88899-56-3 | 816 | C44H65NO13 | Methanol, Ethanol, DMF or DMSO | -20°C |
| Blasticidin S HCl Solution 10mg/ml | B12150 | 3513-03-9 | 458.9 | C17H26N8O5 • HCl | Water | -20°C |
| Blasticidin S Hydrochloride, Powder | B12200 | 3513-03-9 | 458.9 | C17H26N8O5 • HCl | Water | -20°C |
| 17-DMAG | D26100 | 467214-20-6 | 616.8 | C32H48N4O8 | DMSO, Ethanol | -20°C |
| Carbenicillin Disodium Salt | C46000 | 4800-94-6 | 422.4 | C17H16N2Na2O6S | Water | 2-8°C |
| Cefazolin Sodium Salt | C54500 | 27164-46-1 | 476.49 | C14H13N8NaO4S3 | Water | 2-8°C |
| Cefixime Trihydrate | C62720 | 125110-14-7 | 507.5 | C16H15N5O7S2 • 3H2O | - | Room Temperature |
| Cefoperazone Sodium Salt | C57600 | 62893-20-3 | 667.7 | C25H26N9NaO8S2 | Water | 2-8°C |
| Cefotaxime Sodium Salt | C51000 | 64485-93-4 | 477.5 | C16H16N5NaO7S2 | Water | 2-8°C |
| Cefsulodin Sodium Salt | C52000 | 52152-93-9 | 554.5 | C22H19N4NaO8S2 | Water | 2-8°C |
| Ceftazidime Hydrate | C59200 | 72558-82-8 | 546.5 | C22H22N6O7S2 • xH2O | Water | 2-8°C |
| Cefuroxime, Sodium Salt | C56300 | 56238-63-2 | 446.37 | C16H15N4NaO8S | DMSO, Methanol and Water | 2-8°C |
| Cephalexin Monohydrate | C59000 | 23325-78-2 | 365.4 | C16H17N3O4S-H2O | Water | 2-8°C |
| Cephalothin Sodium Salt | C59450 | 58-71-9 | 418.41 | C16H15N2NaO6S2 | Water | 2-8°C |
| Chlortetracycline Hydrochloride | C61040 | 64-72-2 | 515.3 | C22H23ClN2O8 • HCl | Water | -20°C |
| Clindamycin Hydrochloride | C41050 | 21462-39-5 | 461.5 | C18H33ClN2O5 • HCl | Water | 2-8°C |
| Cycloheximide | C81040 | 66-81-9 | 281.35 | C15H23NO4 | Ethanol, methanol | 2-8°C |
| D-Cycloserine | C81000 | 68-41-7 | 102.1 | C3H6N2O2 | Water | 2-8°C |
| Doxorubicin Hydrochloride | D43010 | 25316-40-9 | 580 | C27H29NO11 • HCl | Water | 2-8°C |
| Doxycycline Hydrochloride | D43020 | 10592-13-9 | 480.9 | C22H24N2O8 • HCl | Water | 2-8°C |
| Ertapenem Sodium Salt | E32100 | 153773-82-1 | 497.5 | C22H24N3NaO7S | Water | 2-8°C |
| Erythromycin | E57000 | 114-07-8 | 733.9 | C37H67NO13 | Ethanol | Room Temperature |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:13212737804
邮箱:sales@amyjet.com
0.1691